The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer.
CRC
ICIs
angiogenesis
anti-angiogenics
bevacizumab
colorectal cancer
immune checkpoint inhibitors
immunotherapy
nivolumab
pembrolizumab
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
06 Oct 2022
06 Oct 2022
Historique:
received:
13
09
2022
revised:
30
09
2022
accepted:
02
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Angiogenesis, a hallmark of cancer, plays a fundamental role in colorectal cancer (CRC). Anti-angiogenic drugs and chemotherapy represent a standard of care for treating metastatic disease. Immune checkpoint inhibitors (ICIs) have changed the therapeutic algorithm of many solid tumors. However, the efficacy of ICIs is limited to mCRC patients carrying microsatellite instability (MSI-H), which represent approximately 3-5% of mCRC. Emerging evidence suggests that anti-angiogenic drugs could exhibit immunomodulatory properties. Thus, there is a strong rationale for combining anti-angiogenics and ICIs to improve efficacy in the metastatic setting. Our review summarizes the pre-clinical and clinical evidence regarding the combination of anti-angiogenics and ICIs in mCRC to deepen the possible application in daily clinical practice.
Identifiants
pubmed: 36294987
pii: life12101552
doi: 10.3390/life12101552
pmc: PMC9604892
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Science. 2021 Feb 5;371(6529):602-609
pubmed: 33303685
Lancet Oncol. 2022 Jul;23(7):876-887
pubmed: 35636444
Biomedicines. 2022 Feb 09;10(2):
pubmed: 35203620
Int J Cancer. 2022 Aug 1;151(3):473-480
pubmed: 35429341
CA Cancer J Clin. 2022 Jul;72(4):372-401
pubmed: 35472088
Fam Cancer. 2009;8(3):231-9
pubmed: 19165625
J Clin Oncol. 2020 Jun 20;38(18):2053-2061
pubmed: 32343640
Cancers (Basel). 2021 May 17;13(10):
pubmed: 34067631
Front Immunol. 2020 Nov 11;11:584723
pubmed: 33262763
Signal Transduct Target Ther. 2022 Mar 4;7(1):70
pubmed: 35246503
ESMO Open. 2022 Oct;7(5):100559
pubmed: 36029653
Cancer Res. 2001 Aug 1;61(15):5731-5
pubmed: 11479208
JAMA. 2021 Feb 16;325(7):669-685
pubmed: 33591350
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
J Clin Oncol. 2007 Apr 20;25(12):1539-44
pubmed: 17442997
Clin Cancer Res. 2021 Apr 15;27(8):2139-2147
pubmed: 33495314
Lancet. 2015 May 9;385(9980):1843-52
pubmed: 25862517
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Cell. 1996 Aug 9;86(3):353-64
pubmed: 8756718
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Lancet. 2013 Jan 26;381(9863):303-12
pubmed: 23177514
Nat Med. 2014 Jun;20(6):607-15
pubmed: 24793239
Cancer Treat Rev. 2019 Jun;76:22-32
pubmed: 31079031
Angiogenesis. 2017 May;20(2):185-204
pubmed: 28361267
Int J Mol Sci. 2020 Jun 30;21(13):
pubmed: 32630154
Lancet Oncol. 2015 May;16(5):499-508
pubmed: 25877855
Lancet Oncol. 2015 Oct;16(13):1306-15
pubmed: 26338525
Nat Med. 2003 May;9(5):562-7
pubmed: 12704383
Int J Mol Sci. 2022 Aug 05;23(15):
pubmed: 35955855
Clin Colorectal Cancer. 2022 Jun;21(2):141-148
pubmed: 35101346
Cell. 1994 Jan 28;76(2):301-14
pubmed: 7507411
Nature. 2011 Jul 13;475(7355):226-30
pubmed: 21753853
Cancer J. 2018 Jul/Aug;24(4):193-204
pubmed: 30119083
J Clin Oncol. 2020 Jan 1;38(1):11-19
pubmed: 31725351
Front Immunol. 2015 Nov 24;6:603
pubmed: 26635815
Mol Cancer. 2019 Mar 30;18(1):60
pubmed: 30925919
Cancers (Basel). 2021 Sep 03;13(17):
pubmed: 34503248
Nat Rev Immunol. 2022 Sep;22(9):576-588
pubmed: 35288707
Cancer Treat Rev. 2022 Apr;105:102373
pubmed: 35279535
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Cells. 2022 Jan 19;11(3):
pubmed: 35159131
JAMA Oncol. 2021 Oct 01;7(10):1529-1535
pubmed: 34382998
Semin Cancer Biol. 2021 Nov 25;86(Pt 3):997-1007
pubmed: 34838957
Eur Urol. 2020 Aug;78(2):195-206
pubmed: 32376136
Int J Mol Sci. 2022 Jan 13;23(2):
pubmed: 35055006
J Clin Oncol. 2012 Oct 1;30(28):3499-506
pubmed: 22949147
Cancer Treat Rev. 2020 Jun;86:102017
pubmed: 32335505
Cancer Discov. 2015 Jan;5(1):16-8
pubmed: 25583798
Trends Cancer. 2021 Jul;7(7):647-660
pubmed: 33674230
Eur J Cancer. 2022 Jul;169:93-102
pubmed: 35526308
BMC Cancer. 2017 Jun 9;17(1):408
pubmed: 28599628
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33753566
Cell Rep Med. 2021 Aug 27;2(9):100383
pubmed: 34622226
J Clin Oncol. 2002 Nov 1;20(21):4368-80
pubmed: 12409337
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
ESMO Open. 2020 Sep;5(5):e000753
pubmed: 32912860
Cancers (Basel). 2020 Nov 15;12(11):
pubmed: 33203154
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
J Cancer. 2022 Aug 8;13(10):3091-3102
pubmed: 36046644
J Clin Oncol. 2022 Jan 10;40(2):161-170
pubmed: 34637336
Lancet Oncol. 2015 Oct;16(13):1355-69
pubmed: 26361971
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Cancer Res. 1996 Mar 1;56(5):1111-17
pubmed: 8640769
Lancet Oncol. 2013 Jan;14(1):29-37
pubmed: 23168366
JAMA Netw Open. 2021 Aug 2;4(8):e2118416
pubmed: 34369992
Front Oncol. 2022 Apr 14;12:844801
pubmed: 35494078
Nat Med. 1996 Oct;2(10):1096-103
pubmed: 8837607
J Clin Oncol. 2008 Apr 20;26(12):2013-9
pubmed: 18421054
Nat Med. 2016 Nov;22(11):1342-1350
pubmed: 27694933
Nat Med. 2003 Jun;9(6):653-60
pubmed: 12778163
Oncologist. 2022 Mar 11;27(3):198-209
pubmed: 35274710